Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model

Basit Öğe Kaydı
dc.authoridkempster, sarah/0000-0002-4309-1489
dc.authoridSalguero, Francisco Javier/0000-0002-5315-3882
dc.authoridCharlton, Frank/0000-0003-2892-3555
dc.contributor.authorKempster, Sarah
dc.contributor.authorHassall, Mark
dc.contributor.authorGraham, Victoria
dc.contributor.authorKennedy, Emma
dc.contributor.authorFindlay-Wilson, Stephen
dc.contributor.authorSalguero, Francisco J.
dc.contributor.authorBagci, Binnur
dc.date.accessioned2024-10-26T18:11:35Z
dc.date.available2024-10-26T18:11:35Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractCrimean-Congo Haemorrhagic Fever Virus (CCHFV) is spread by infected ticks or direct contact with blood, tissues and fluids from infected patients or livestock. Infection with CCHFV causes severe haemorrhagic fever in humans which is fatal in up to 83 % of cases. CCHFV is listed as a priority pathogen by the World Health Organization (WHO) and there are currently no widely-approved vaccines. Defining a serological correlate of protection against CCHFV infection would support the development of vaccines by providing a 'target threshold' for pre-clinical and clinical immunogenicity studies to achieve in subjects and potentially obviate the need for in vivo protection studies. We therefore sought to establish titratable protection against CCHFV using pooled human convalescent plasma, in a mouse model. Convalescent plasma collected from seven individuals with a known previous CCHFV virus infection were characterised using binding antibody and neutralisation assays. All plasma recognised nucleoprotein and the Gc glycoprotein, but some had a lower Gn glycoprotein response by ELISA. Pooled plasma and two individual donations from convalescent donors were administered intraperitoneally to A129 mice 24 h prior to intradermal challenge with CCHFV (strain IbAr10200). A partial protective effect was observed with all three convalescent plasmas characterised by longer survival post-challenge and reduced clinical score. These protective responses were titratable. Further characterisation of the serological reactivities within these samples will establish their value as reference materials to support assay harmonisation and accelerate vaccine development for CCHFV.
dc.description.sponsorshipInnovate UK [97163, 732732]
dc.description.sponsorshipThis study was funded in part by a grant from Innovate UK, Sero- logical Vaccines Standards for Emerging Diseases, Grant No: 97163. Authors also acknowledge contribution of funding for securing dona- tions collected under EU-H2020 CCHFVaccine project (ref: 732732) .
dc.identifier.doi10.1016/j.virusres.2024.199409
dc.identifier.issn0168-1702
dc.identifier.issn1872-7492
dc.identifier.pmid38815869
dc.identifier.scopus2-s2.0-85194963829
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.virusres.2024.199409
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30746
dc.identifier.volume346
dc.identifier.wosWOS:001249451700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofVirus Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCCHF
dc.subjectCCHFV
dc.subjectImmunity
dc.subjectInfection
dc.subjectMouse model
dc.subjectConvalescent
dc.subjectVaccine
dc.titleConvalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu